Infused chemotherapy use in the elderly after patent expiration

American Journal of Managed Care

Volumn 18, Issue 5, 2012, Pages

  Conti, Rena M ^a   Rosenthal, Meredith B ^b   Polite, Blase N ^a   Bach, Peter B ^c   Shih, Ya Chen Tina ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CLINICAL DECISION MAKING; COLORECTAL CANCER; COST CONTROL; CROSS-SECTIONAL STUDY; EXPIRATION DATE; HEALTH CARE POLICY; HUMAN; MEDICARE; METASTATIC COLORECTAL CANCER; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COST SAVINGS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PATENTS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; TIME FACTORS; UNITED STATES;

EID: 84864413549     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Aitken M, ER Berndt, DM Cutler: Prescription drug spending trends in the United States; looking beyond the turning point. Health Aff (Millwood) 28:w151-w160, 2009
2. Mullins CD, DeVries AR, Hsu VD, et al: Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood) 24:1117-1127, 2005 (Pubitemid 41058612)
3. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005 (Pubitemid 41520077)
4. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351: 317-319, 2004
5. Yabroff KR, Lamont EB, Mariotto A, et al: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630-641, 2008
6. Mayer RJ: Targeted therapy for advanced colorectal cancer: More is not always better. N Engl J Med 360:623-625, 2009
7. Food, Drug, and Cosmetic Act. 21 USC 355(j) § 505(j)
8. Scherer FM: Pricing, profits, and technological progress in the pharmaceutical industry. J Economic Perspect 7:97-115, 1993
9. 69 Federal Register 55763, 2004. (codified at 42 CFR 405, 410, 411, 414, 418, 424, 484, 486)
10. Patient Protection and Affordable Care Act. Pub L 111-148. Title VII: Improving Access to Innovative Medical Therapies. Subtitle A: Biologics Price Competition and Innovation. Sec 7002: Approval Pathway for Biosimilar Biological Products
11. Department of Health and Human Services: Office of the Inspector General: Medicare payments for newly available generic drugs. http://oig.hhs.gov/oei/ reports/oei-03-09-00510.pdf
12. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
13. Harlan LC, Greene AL, Clegg LX, et al: Insurance status and the use of guidance therapy in the treatment of selected cancers. J Clin Oncol 23:9079-9088, 2005
14. Panattoni LE: The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J Health Econ 30:126-145, 2011
15. Cutrona SL, Woolhandler S, Lasser KE, et al: Recipients of free prescription drug samples: A nationally representative analysis. Am J Public Health 98:284-289, 2008 (Pubitemid 351317563)
16. Branstetter LG, Chatterjee C, Higgins M: Regulation and welfare: Evidence from Paragraph IV generic entry in the pharmaceutical industry. National Bureau of Economic Research Working Paper No. 17188, 2011
17. Lakdawalla D, Philipson T, Wang YR: Intellectual property and marketing. National Bureau of Economic Research Working Paper No. 12577, 2006
18. Berndt, ER, Kyle MK, Ling DC: The long shadow of patent expiration: Generic entry and Rx-to-OTC switches, in Feenstra RC, Shapiro MD (eds): Scanner Data and Price Indexes. Chicago, IL, University of Chicago Press, 2003
19. Huskamp HG, Donohue JM, Koss C, et al: Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics 26:603- 616, 2008
20. Huckfeldt PJ, Knittel CR: Pharmaceutical use following generic entry: Paying less and buying less. http://web.mit.edu/knittel/www/papers/hk-latest.pdf
21. CenterWatch: FDA drugs approved for oncology. http://www.centerwatch.com/ drug-information/fda-approvals/drug-areas.aspx?AreaID=12
22. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLRIFI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meirdionale.J Clin Oncol 23:4866-4875, 2005 (Pubitemid 46223991)
23. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
24. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the firstline treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25:164s, 2007 (suppl; abstr 4000)
25. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:5s, 2008 (suppl; abstr 2)
26. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
27. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319, 2008
28. Abrams TA, Brightly R, Mao J, et al: Patterns of adjuvant chemotherapy use in a population based cohort of patients with resected stage II or stage III colon cancer. J Clin Oncol 29:3255-3262, 2011
29. Centers for Medicare & Medicaid Services: New April 2005 quarterly average sales price (ASP) Medicare Part B drug pricing file and revisions to January 2005 quarterly average sales price (ASP) Medicare Part B drug pricing file. http://www.cms.gov/mlnmattersarticles/downloads/MM3846.pdf
30. First DataBank: PricePoint Rx. http://www.firstdatabank.com/Products/ price-point-rx.aspx
31. Greene WH: Econometric Analysis (ed 5). Upper Saddle River, NJ, Prentice Hall, 2005, pp 285, 291, 293, 304
32. Wooldridge JM: Introductory Econometrics: A Modern Approach (ed 4). Mason, OH, South-Western Publishing, 2008, p 435
33. American College of Gastroenterology: Colorectal cancer screening.http://patients.gi.org/topics/colorectal-cancer-screening/
34. Friedman JY, Curtis LH, Hammill BG, et al: The Medicare Modernization Act and reimbursement for outpatient chemotherapy: Do patients perceive changes in access to care? Cancer 110:2304-2312, 2007 (Pubitemid 350100753)
35. Carino T, Williams RD 2nd, Colbert AM, et al: Medicare's coverage of colorectal cancer drugs: A case study in evidence development and policy. Health Aff (Millwood) 25:1231-1239, 2006 (Pubitemid 44497621)
36. Hurwitz MA, Caves RE: Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 31:299-320, 1988
37. Jacobson M, Earle CC, Price M, et al: How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) 29:1391-1399, 2010
38. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 25:437-443, 2006 (Pubitemid 43529552)
39. Centers for Medicare & Medicaid Services: 2008 Characteristics and perceptions of the Medicare population sourcebook, section 1. http://www.cms.gov/MCBS/DT/list.asp
40. Pfizer: 2010 annual report. http://www.pfizer.com/files/annualreport/ 2010/annual/review2010.pdf
41. Malin JL, Schneider EC, Epstein AM, et al: Results of the National Initiative for Cancer Care Quality: How can we improve the quality of cancer care in the United States? J Clin Oncol 24:626-634, 2006 (Pubitemid 46630426)